FDA SUPPLEMENTAL USE REVIEW STREAMLINING ENDORSED BY DANA FARBER's CHABNER; AGENCY SHOULD PUBLICIZE CLINICAL TRIAL INFORMATION -- KIDNEY CANCER ASSOCIATION
Executive Summary
Supplemental indications should be reviewed under a streamlined process at FDA, former National Cancer Institute Cancer Treatment Director Bruce Chabner, MD, recommended to the House Commerce/Health Subcommittee Feb. 27.
You may also be interested in...
PhRMA Launches Medicare Ad Campaign Through Advocacy Coalition
The Pharmaceutical Research & Manufacturers of America will roll out its ad campaign on the Medicare drug benefit nationwide in August through the recently formed Citizens for Better Medicare, headed by former PhRMA Advertising Director Tim Ryan.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011